Physician profile
Jenny Eileen Murase
NPI 1346371382
$1,050,669.76
in general payments reported to CMS, 2019-2025
24 companies · $550K in 2025
The $550K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $43K · 2021: $16K · 2022: $46K · 2023: $65K · 2024: $272K · 2025: $550K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $732K · Consulting Fee: $90K · Travel and Lodging: $49K · Food and Beverage: $16K · Education: $336 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $731,639.02 |
| Consulting Fee | $90,317.27 |
| Travel and Lodging | $49,157.06 |
| Food and Beverage | $16,229.17 |
| Education | $335.63 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $250,164.07 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $248,291.10 | 2019-2025 | Dupixent |
| Genzyme Corporation | $228,834.20 | 2019-2025 | |
| Galderma Laboratories, L.P. | $157,748.79 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $81,982.43 | 2024-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $29,226.81 | 2021-2025 | Anzupgo, Adbry |
| Abbvie INC. | $22,130.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $7,370.93 | 2023-2025 | Sotyktu |
| Ucb Sa | $6,999.34 | 2019-2020 | |
| Pfizer INC. | $6,311.89 | 2022-2025 | |
| Eli Lilly and Company | $4,181.10 | 2020-2023 | |
| Sanofi US Services INC. | $2,870.00 | 2025 | |
| Arcutis Biotherapeutics, INC. | $2,754.61 | 2023-2025 | Zoryve |
| Allerderm Laboratories | $1,000.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $195.72 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $139.59 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $106.87 | 2024-2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Incyte Corporation | $86.62 | 2022-2025 | Opzelura |
| Amgen INC. | $60.23 | 2025 | Otezla, Otezla |
| Genentech USA, INC. | $44.35 | 2024 | Xolair |
| Organon LLC | $28.14 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.22 | 2025 | Cabtreo, Jublia, Siliq |
| Verrica Pharmaceuticals INC. | $18.77 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Murase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.